ISN

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Brian Callahan Named CEO, Joe Eastin Named Executive Chairman of ISN®

Retrieved on: 
Tuesday, January 16, 2024

Brian succeeds prior CEO Joe Eastin, who is now Executive Chairman.

Key Points: 
  • Brian succeeds prior CEO Joe Eastin, who is now Executive Chairman.
  • Joe is a remarkable person and an inspiring entrepreneur, and I want to thank him and our Board of Directors for their trust and confidence in me,” said Brian Callahan, CEO and President at ISN.
  • I am most excited about our future and am honored to continue to serve ISN as Executive Chairman.
  • I have no doubt our CEO role is in good hands with Brian Callahan,” said Joe Eastin, Executive Chairman at ISN.

De Grey Mining Selects ISNetworld for Contractor Management

Retrieved on: 
Wednesday, December 20, 2023

ISN , the global leader in contractor and supplier information management services, announced that De Grey Mining Ltd. (ASX: DEG) ("De Grey") has selected ISNetworld as its primary contractor information management system.

Key Points: 
  • ISN , the global leader in contractor and supplier information management services, announced that De Grey Mining Ltd. (ASX: DEG) ("De Grey") has selected ISNetworld as its primary contractor information management system.
  • ISN will assist De Grey with enhancing its contractor management process through all aspects of review and verification, contractor communication and compliance, scorecard creation, and ongoing monitoring.
  • De Grey is a Western Australian gold explorer and project developer.
  • “ISN’s global leadership in contractor management, along with its team’s local presence in Perth, made it a strong match for De Grey to partner with to move our contractor management programs forward,” said Peter Holmes, Project Director at De Grey Mining.

ISN® Releases Latest Serious Injuries and Fatalities Insights Report

Retrieved on: 
Monday, December 18, 2023

ISN , the global leader in contractor and supplier information management services, released its latest Serious Injuries and Fatalities (SIFs) White Paper.

Key Points: 
  • ISN , the global leader in contractor and supplier information management services, released its latest Serious Injuries and Fatalities (SIFs) White Paper.
  • The analysis of more than 127,000 recordable incidents from 2017-2022 showed nearly 24,000 SIFs cases, including more than 20,000 hospitalizations, 3,154 amputations and 871 fatalities.
  • Interestingly, the highest rate of fatalities is not correlated with the largest company size, but rather mid-size corporations.
  • While serious events are occurring, it is at a lower rate than many other industries.

ISN® Introduces New Proprietary AI Engine, InsightAI

Retrieved on: 
Tuesday, November 28, 2023

ISN , the global leader in contractor and supplier information management services, announced the launch of InsightAI, ISN’s new proprietary generative artificial intelligence (AI) engine.

Key Points: 
  • ISN , the global leader in contractor and supplier information management services, announced the launch of InsightAI, ISN’s new proprietary generative artificial intelligence (AI) engine.
  • InsightAI uses AI to analyze data sets to classify and extract information based on identified patterns and themes.
  • This technology enables ISN customers to consume and synthesize large volumes of data more efficiently.
  • Additionally, InsightAI helps hiring organizations immediately discover consistent themes by summarizing thousands of free-text comments into five specific strengths and opportunities.

ISN Contractors Significantly Outperform Industry Peers on Safety Results

Retrieved on: 
Wednesday, October 25, 2023

The new study, “Evolving Contractor Safety Through the Use of ISN Data,” researched NAICS code work types across multiple industries ranging from construction to facility management and found that more than 85% of ISN contractors significantly outperform their industry peers’ Total Recordable Incident Rates (TRIR), averaging 50% or less of the TRIR of their industry grouping’s average rate.

Key Points: 
  • The new study, “Evolving Contractor Safety Through the Use of ISN Data,” researched NAICS code work types across multiple industries ranging from construction to facility management and found that more than 85% of ISN contractors significantly outperform their industry peers’ Total Recordable Incident Rates (TRIR), averaging 50% or less of the TRIR of their industry grouping’s average rate.
  • Additionally, of 26 NAICS classified “work types”, ISN-subscribed contractors outperform industry peers in 100% of those categories.
  • This is clear evidence that ISNetworld subscribed contractors are held to higher standards and perform safer work when compared to industry peers.
  • To learn more about ISNetworld and how the platform is enabling better results and safety for contractors, visit: https://www.isnetworld.com

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

ISN Acquires Leading Responsible Sourcing Platform Transparency-One

Retrieved on: 
Thursday, September 7, 2023

Efforts were led by Executive Vice President & General Counsel, Jim Skochdopole and Vice President, Joe Schloesser from ISN with transaction guidance from Blackstone Growth, which made a strategic growth investment in ISN in 2020.

Key Points: 
  • Efforts were led by Executive Vice President & General Counsel, Jim Skochdopole and Vice President, Joe Schloesser from ISN with transaction guidance from Blackstone Growth, which made a strategic growth investment in ISN in 2020.
  • Founded in 2016 with offices in Boston, Massachusetts and Paris, France, Transparency-One’s platform empowers organizations to delve deeply into their supply chains, allowing them to gain unique insights into product visibility, traceability, supply chain mapping, responsible sourcing and sustainability.
  • We look forward to helping accelerate Transparency-One’s mission while continuing to enhance the ISNetworld platform.
  • ISN was the best candidate to acquire our company and become the worldwide leader in this market.”
    Chris Morrison, Senior Managing Director of Transparency-One, said: “Transparency-One's data-driven approach to ensuring responsible sourcing is a perfect fit for ISN.

Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

Retrieved on: 
Monday, August 7, 2023

GARDEN CITY, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced the presentation of data that support the ongoing preclinical development of selective neuronal nitric oxide synthase (nNOS) inhibibitors for the treatment of Autism Spectrum Disorder (ASD). These data will be presented by the Amal Lab from the Hebrew University of Jerusalem (HUJI) in a poster at the Annual International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meetings, which are being held in Portugal from August 8th - 11th.

Key Points: 
  • Research conducted recently at HUJI has shown that mutation in the CNTNAP2 gene increases NO formation in the brain of the ASD mouse model.
  • These data demonstrate that the inhibition of NO production may reverse ASD phenotypes, and provide further evidence that NO is a pathologic factor in autism.
  • These results have led researchers to believe that NO is a novel target for the treatment of ASD and other neurological disorders.
  • The preclinical data developed thus far show that this exciting novel approach to treating ASD has the potential to address a significant unmet medical need.